US Urological Science

Genetic Testing for Hereditary Prostate Cancer in Australia

Prostate cancer is common in Australia, and most cases are not caused by one inherited gene. Hereditary prostate cancer matters because a germline variant can raise risk, reveal a broader cancer syndrome, guide treatment and give relatives a clear route to testing. Recommendations have shifted as evidence and targeted therapies have improved, so current decisions depend on disease stage, family history and tumour findings as well as age at diagnosis.

A family history remains important, but it is not a simple yes-or-no test. Risk can be higher when a father, brother or son has prostate cancer, when several relatives are affected, or when diagnosis occurs at a younger age. A paternal history is just as relevant as a maternal one. Clinicians may hear patients say that cancer “runs in the family”, so specific relationships, ages at diagnosis and other affected cancers must be established.

Current guidance is broader than the older model of testing only people with an obvious family cluster. Germline testing is strongly considered for metastatic prostate cancer, even when family history is unremarkable, because inherited variants can influence systemic treatment and eligibility for clinical trials. Earlier-onset disease, unusual ancestry and pathogenic variants found in the tumour can also justify referral to a genetics service.

Australian practice begins with a general practitioner, often in a shared decision about PSA testing because Australia has no population-wide prostate screening programme. Referral, public genetics services and private testing operate through different funding and waiting-list arrangements. People outside major cities may use telehealth, while families can be spread across states. These practical differences make it useful to ask a clinician what a test will cost and who will interpret the result.

Who should consider genetic testing

Assessment starts with age at diagnosis, stage, ancestry, previous cancers and a three-generation family history. Current National Comprehensive Cancer Network and European Association of Urology guidance supports considering germline testing in metastatic disease and in selected people with high-risk non-metastatic disease.

Clinical situation Recommended approach Why it matters
Metastatic prostate cancer Offer or strongly consider germline testing, even without a known family history Results may influence targeted treatment, trial eligibility and testing of relatives
Several affected relatives, a father-and-son pattern or diagnosis before 55 Seek a genetics assessment and consider a germline panel Age and family pattern may indicate meaningful inherited susceptibility
Another hereditary breast, ovarian, pancreatic or Lynch-associated cancer Request referral to a clinical genetics service Prostate cancer may be the first presentation of a broader cancer syndrome
Average-risk, non-metastatic disease without suggestive family or tumour findings Routine hereditary testing is not generally recommended Broad commercial testing may add uncertainty without changing clinical care

Family history details should be specific: which relatives had cancer, their age at diagnosis, biological relationship and any other inherited cancer. One affected father may warrant discussion, while multiple affected relatives or prostate cancer before age 55 generally strengthens the case for formal assessment. A young relative with an aggressive tumour may also change the pathway.

Testing should be offered with pre-test counselling, written consent and a plan for relatives. Clear explanations are essential; research into stuttering communication demonstrates how speech support improves understanding, and the same principle applies when families receive information about an inherited cancer risk.

What the test can reveal

A laboratory-accredited germline panel should cover genes with actionable clinical value, commonly BRCA2, BRCA1, ATM, PALB2, CHEK2 and HOXB13, plus mismatch-repair genes such as MLH1, MSH2, MSH6 and PMS2. The exact panel depends on clinical context, laboratory and local reimbursement. A useful report states whether a variant is pathogenic, likely pathogenic or uncertain, and whether testing adequately covered deletions, duplications and relevant family variants.

Tumour and germline results answer different questions. Prostate tumours are commonly screened for homologous-recombination repair defects and mismatch repair; an abnormality can trigger targeted treatment assessment and germline confirmation. A mutation seen only in the tumour may be acquired, while a variant found in blood or saliva is potentially inherited and should be confirmed according to laboratory protocols.

A negative panel does not rule out inherited susceptibility, and a variant of uncertain significance should not be treated as a positive result. Polygenic or familial risk scores may refine estimates for some families, but they do not replace clinical testing or high-risk follow-up. Direct-to-consumer tests can also report numerous uncertain findings, making professional interpretation important.

Long-term evidence matters in urology. The wider journal publishes research on hypospadias repair outcomes, which follows children into adulthood. That work concerns paediatric surgery rather than prostate cancer, yet illustrates the value of reliable longitudinal records and planned follow-up; it is not evidence of inherited prostate cancer risk.

How the Australian pathway works

In Australia, a GP commonly coordinates the pathway. The clinician can confirm whether prostate cancer has been diagnosed, gather pathology and family-history details, and refer to a state-based genetics service or a urologist or oncologist with genetics expertise. Public genetics services may be free at the point of care after referral, although eligibility rules and queues vary between states and territories.

Medicare support depends on the test and pathway. A clinically relevant test ordered by an eligible clinician may attract a Medicare benefit, and some tumour tests used for targeted treatment are subsidised, but many broad commercial panels are paid privately. Private laboratories can offer faster testing and different panel choices. Patients should request a written estimate that includes the laboratory fee, consultation, follow-up and any family-member testing.

Geography still matters. Families in regional and remote areas may use telehealth links to genetics teams in Melbourne, Sydney, Brisbane, Adelaide or Perth, and relatives can sometimes be tested in different states. Privacy deserves attention because results may affect relatives who did not consent to testing. Australia’s multicultural communities also need ancestry-aware interpretation, as some populations remain underrepresented in genomic studies.

Understanding results and family communication

The practical value of a report depends on the type of finding. Common outcomes include:

A family should understand the difference between a personal cancer risk, a familial variant and a statistical family-history score. When a familial variant is identified, relatives can usually first test for that specific variant rather than paying for another broad panel. The person who tested first may also need an updated copy of the laboratory report for other relatives and their own doctors.

Before a genetics appointment, gather the following:

Lifestyle measures cannot erase an inherited variant, but exercise, weight management, smoking cessation and control of blood pressure and diabetes support general health and may influence prostate-cancer outcomes. Australian guidance on healthy lifestyle resources can complement specialist care, though supplements and wellness programs cannot replace surveillance or hereditary risk assessment.

Preparing for the next clinical step

Before testing, ask what genes the panel covers, the expected turnaround time, the cost, how uncertain results are handled and whether the laboratory is accredited. After testing, obtain a written summary and discuss how any result would affect PSA surveillance, imaging, surgery, systemic therapy or family screening. Counselling should also cover privacy, possible insurance implications and the emotional effect on relatives.

Evidence continues to evolve, so guidelines and laboratory panels need regular review. Urological Science publishes original urology research, abstracts, full text and open-access articles; prospective contributors can consult its author instructions. Readers should compare study findings with current clinical guidance rather than treating one published association as a personal diagnosis.

If you have prostate cancer before 55, metastatic disease, several affected relatives or another cancer linked to an inherited syndrome, book an appointment with your GP and ask whether a genetics referral is appropriate. Bring pathology reports, a list of relatives and ages at diagnosis, and relevant records from other cancer diagnoses. Leave the appointment with a clear testing plan, an estimate of costs and an agreed route for follow-up.